ANTI-PAF ANTIBODIES

• US 20110212088A1
• Filed: 02/25/2011
• Published: 09/01/2011
• Est. Priority Date: 02/26/2010
• Status: Abandoned Application

• Current Assignee: Jonathan Michael Wojciak, Roger A. Sabbadini
• Original Assignee: Jonathan Michael Wojciak, Roger A. Sabbadini
• Inventors: SABBADINI, Roger A., WOJCIAK, Jonathan Michael
• Application Number:
  US13/035,821
• Publication Number:
  US 20110212088A1
• Time in Patent Office: Days
• US Class Current: 424/133.1
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C07F 9/106 Adducts, complexes, salts of phosphatides
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 2317/33 Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: G01N 2405/04 Phospholipids, i.e. phosphoglycerides
• CPC Class Codes: G01N 33/86 involving blood coagulating time or factors, or their receptors

Abstract

Monoclonal antibodies to platelet activating factor (PAF) are described, along with methods for their production and use. Such antibodies can be formulated and used for therapeutic purposes, as well as for diagnosis and detection.

Claims

1. An isolated monoclonal antibody, or an antigen binding fragment thereof, that binds platelet activating factor (PAF), wherein the isolated antibody or antigen binding fragment thereof optionally comprises at least one heavy chain variable region and at least one light chain variable region, wherein each light chain variable region comprises at least one of the following light chain CDRs:

(i) a CDRL1 comprising the amino acid sequence ITTTDIKRNMN (SEQ ID NO;

     3) or a variant thereof in which from 1 to 10 amino acids residues are substituted with a different amino acid residue;

(ii) a CDRL2 comprising the amino acid sequence QGNILRP (SEQ ID NO;

     4) or a variant thereof in which from 1 to 6 amino acids residues are substituted with a different amino acid residue; and

(iii) a CDRL3 comprising the amino acid sequence LQSRGLPFT (SEQ ID NO;

     5) or a variant thereof in which from 1 to 8 amino acids residues are substituted with a different amino acid residue.

2. An isolated antibody or antigen binding fragment of claim 1 that comprises a light chain variable domain comprising a sequence of amino acid residues having an amino acid sequence selected from the group consisting of:

a.

3. An isolated antibody or antigen binding fragment according to claim 1 wherein at least one amino acid residue of the antibody or antigen binding fragment is glycosylated.

4. An isolated humanized antibody according to claim 1 that comprises two heavy chains and two light chains.

5. A pharmaceutical composition comprising an isolated antibody or antigen binding fragment according to claim 1 and a pharmaceutically acceptable carrier.

6. A method selected from the group consisting of:

a. a method of reducing inflammation, allergic response or immune response in a subject, comprising administering to a subject having undesired inflammation, allergic response or immune response a therapeutically effective amount of an isolated antibody, or an antigen binding fragment thereof, according to claim 1; and

b. a method of treating a disease or condition in a subject, comprising administering to a subject a therapeutically effective amount of an isolated antibody, or an antigen binding fragment thereof, according to claim 1, wherein the disease or condition is an inflammatory diseases or condition, a disease or condition having an inflammatory component, an autoimmune disease or condition, an allergic condition, inflammatory bowel disease, ulcerative colitis, Crohn'"'"'s disease, spondyloarthropathy, osteoarthritis, rheumatoid arthritis, multiple sclerosis, immune suppression, systemic lupus erythematosis, psoriasis, asthma, glomerulonephritis, thyroiditis, chondrocalcinosis, acute lung injury, sepsis, ischemia-reperfusion injury, acute respiratory distress syndrome, neuropathic pain, hydrostatic pulmonary edema or trauma.

10. A method selected from the group consisting of:

a. a method of detecting platelet activating factor (PAF) or a metabolite thereof in a sample, comprising detecting binding of PAF or a metabolite thereof in a sample to an anti-PAF antibody or antigen binding fragment thereof of claim 1 under conditions that allow the anti-PAF antibody to bind to the PAF or metabolite thereof, if present in the sample;

b. a method of detecting in a sample a platelet activating factor (PAF) binding agent comprising contacting a sample with a diagnostic device bearing a diagnostic reagent according to claim 7, wherein the reactive group of the diagnostic reagent optionally is a sulfhydryl (thiol) group and wherein the diagnostic reagent optionally comprises a label, wherein the label optionally is biotin.

11. A method according to claim 10 wherein the sample is a tissue sample, optionally a biopsy sample, and a fluid sample, wherein the fluid sample optionally is selected from the group consisting of whole blood, plasma, serum, urine, semen, bile, aqueous humor, vitreous humor, synovial fluid, bronchioalveolar lavage fluid, mucous, and sputum.

7. A diagnostic reagent comprising a derivatized platelet activating factor (PAF), wherein said derivatized PAF comprises a polar head group and at least one hydrocarbon chain, wherein a carbon atom within a hydrocarbon chain is derivatized with a reactive group, wherein the reactive group optionally is a sulfhydryl (thiol) group, and wherein the derivatized PAF optionally is (i) associated with a solid support, wherein the association optionally is a covalent association, or (ii) conjugated to a carrier moiety, wherein the carrier moiety optionally is selected from the group consisting of polyethylene glycol, colloidal gold, adjuvant, a silicone bead, and a protein, wherein the protein is optionally selected from the group consisting of keyhole limpet hemocyanin, albumin, ovalbumin, bovine thyroglobulin, and soybean trypsin inhibitor.

8. An ELISA kit comprising a diagnostic reagent according to claim 7 and an agent that binds PAF under physiological conditions, wherein the agent optionally is an antibody, or an antigen binding fragment thereof, that binds PAF.

9. A method of detecting a platelet binding factor (PAF) binding agent in a biological sample, comprising detecting binding of a PAF binding agent in a biological sample to a diagnostic reagent according to claim 7 under conditions that allow the diagnostic reagent to bind the PAF binding agent, if present in the sample, wherein (i) the PAF binding agent optionally is an antibody, antibody fragment or antibody derivative, and (ii) the biological sample optionally is selected from the group consisting of a tissue sample, optionally a biopsy sample, and a fluid sample, wherein the fluid sample optionally is selected from the group consisting of whole blood, plasma, serum, urine, semen, bile, aqueous humor, vitreous humor, synovial fluid, bronchioalveolar lavage fluid, mucous, and sputum.